» Articles » PMID: 35867923

Study of the Indications for Macrolide Prescriptions in a Colombian Population

Abstract

Introduction: The inappropriate use of antibiotics is associated with a greater risk for antimicrobial resistance, high health care costs, adverse events, and worse clinical outcomes.

Objective: To determine the prescription patterns and approved and nonapproved indications for macrolides in a group of patients from Colombia.

Materials And Methods: This was a cross-sectional study on the indications for the use of macrolides in outpatients registered in a drug-dispensing database of approximately 8.5 million people affiliated with the Colombian health system. Sociodemographic, pharmacological, and clinical variables were considered.

Results: A total of 9.344 patients had received a macrolide prescription; their median age was 40.1 years (interquartile range: 27.1-53.3 years) and 58.3% were women. The most commonly prescribed macrolide was azithromycin (38.8%) most frequently for Helicobacter pylori infection (15.9%) and pneumonia treatment (15.8%). A total of 31.3% of the prescriptions were used for unapproved indications: common cold (7.8%), COVID-19 (4.0%), and acute bronchitis (3.5%). Residence in the Caribbean region (OR=1.17; 95%CI 1.05-1.31), dental prescriptions (OR=2.75; 95%CI 1.91-3.96), presence of chronic respiratory comorbidities (OR=1.30; 95%CI 1.08-1.56), and prescription of erythromycin (OR=3.66; 95%CI 3.24-4.14) or azithromycin (OR=2.15; 95%CI 1,92-2.41) were associated with a higher probability of macrolide use for unapproved indications while being 18-64 years old (OR=0.81; 95%CI 0.71-0.93) or 65 years or older (OR=0.77; 95%CI 0.63-0.94) and residing in Bogotá-Cundinamarca (OR=0.74; 95%CI 0.65-0.85) were associated with reduced risk.

Conclusions: Most patients received macrolides for respiratory tract infections; erythromycin and azithromycin were used for unapproved indications in people under 18 years of age and those with chronic respiratory diseases.

Citing Articles

Coinfections and Superinfections Associated with COVID-19 in Colombia: A Narrative Review.

Duenas D, Daza J, Liscano Y Medicina (Kaunas). 2023; 59(7).

PMID: 37512147 PMC: 10385172. DOI: 10.3390/medicina59071336.


Antibiotic Management of Uncomplicated Skin and Soft Tissue Infections in the Real World.

Valladales-Restrepo L, Aristizabal-Carmona B, Giraldo-Correa J, Acevedo-Medina L, Valencia-Sanchez L, Acevedo-Lopez D Microorganisms. 2023; 11(6).

PMID: 37374871 PMC: 10302172. DOI: 10.3390/microorganisms11061369.


Study of Prescription-Indication of Outpatient Systemic Anti-Fungals in a Colombian Population. A Cross-Sectional Study.

Valladales-Restrepo L, Ospina-Cano J, Aristizabal-Carmona B, Lopez-Caicedo D, Toro-Londono M, Gaviria-Mendoza A Antibiotics (Basel). 2022; 11(12).

PMID: 36551462 PMC: 9774786. DOI: 10.3390/antibiotics11121805.

References
1.
King L, Lovegrove M, Shehab N, Tsay S, Budnitz D, Geller A . Trends in US Outpatient Antibiotic Prescriptions During the Coronavirus Disease 2019 Pandemic. Clin Infect Dis. 2020; 73(3):e652-e660. PMC: 7799289. DOI: 10.1093/cid/ciaa1896. View

2.
Sanchez-Huesca R, Lerma A, Guzman-Saldana R, Lerma C . Prevalence of Antibiotics Prescription and Assessment of Prescribed Daily Dose in Outpatients from Mexico City. Antibiotics (Basel). 2020; 9(1). PMC: 7168224. DOI: 10.3390/antibiotics9010038. View

3.
Dinos G . The macrolide antibiotic renaissance. Br J Pharmacol. 2017; 174(18):2967-2983. PMC: 5573421. DOI: 10.1111/bph.13936. View

4.
Hussain A, Paudyal V, Hadi M . Impact of the COVID-19 Pandemic on the Prescribing Patterns of First-Line Antibiotics in English Primary Care: A Longitudinal Analysis of National Prescribing Dataset. Antibiotics (Basel). 2021; 10(5). PMC: 8156075. DOI: 10.3390/antibiotics10050591. View

5.
Gebeyehu E, Bantie L, Azage M . Inappropriate Use of Antibiotics and Its Associated Factors among Urban and Rural Communities of Bahir Dar City Administration, Northwest Ethiopia. PLoS One. 2015; 10(9):e0138179. PMC: 4574735. DOI: 10.1371/journal.pone.0138179. View